Pipeline
We are passionately advancing a biosimilar portfolio of insulin analogues that are lifeline of insulin-dependent diabetes patients across the globe. Our insulin products include long acting, short-acting, rapid acting and are developed within the framework of rigorous scientific, technical, quality and global regulatory expectations.
GEN1501
- GEN1501 is a biosimilar to Lantus® (Insulin Glargine). Insulin Glargine is a long-acting human insulin analog.
- it is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus.
GEN1504
- GEN1504 is a biosimilar to Humalog® (Insulin Lispro). Insulin Lispro is a rapid acting human insulin analog.
- It is indicated to improve glycemic control in adults and children with diabetes mellitus.
GEN1503
- GEN1503 is a biosimilar to NovoRapid®/NovoLog® (Insulin Aspart). Insulin Aspart is a rapid acting human insulin analog.
- It is indicated to improve glycemic control in adults and children with diabetes mellitus
GEN1502
- GEN1502 is a Biosimilar to Humulin® R (Insulin Human). Human Insulin is a short acting.
- It is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.